Noradrenaline-sensitive adenylate cyclase in rat limbic forebrain homogenates: effects of agonists and antagonists

A.S. HORN* & O.T. PHILLIPSON

M.R.C. Neurochemical Pharmacology Unit, Department of Pharmacology, Medical School, Hills Road, Cambridge, CB2 2QD

Recently Chasin, Mamrak & Samaniego (1974) have demonstrated an adenylate cyclase system in cell-free homogenates of guinea-pig brain that is sensitive to low concentrations of noradrenaline and adrenaline. Blumberg, Taylor & Sulser (1975) have shown that an adenylate cyclase in rat limbic forebrain slices can be specifically stimulated by low concentrations of noradrenaline (EC₅₀ = $2.7 \times$

10⁻⁶M) whilst dopamine is inactive. It is also known that various neuroleptics antagonize this effect (Blumberg & Sulser, 1974; Blumberg et al., 1975). We now report the pharmacological properties of a noradrenaline sensitive adenylate cyclase in homogenates of the rat limbic forebrain. Slices of rat forebrain were prepared by making two coronal cuts, the first being at the optic chiasm, and the second 3 mm further rostral. From this slice the corpus striatum and the adjacent cortex were removed. The tissue homogenization and incubation conditions were essentially those of Chasin et al. (1974); in the initial preincubation adenine (1.0 µM) was added. Cyclic AMP concentrations were estimated by the method of Brown, Ekins & Albano (1972). The concentration of 1-NA required for half-maximal stimulation (EC₅₀) was $8.5 \times 10^{-7} M$ (Table) and

Cyclic AMP production in rat limbic forebrain homogenates

Agonists	Max. stimulation %	$EC_{so}(M)$	
(—)-Isoprenaline	100	2.0×10^{-7}	
()-Noradrenaline	100	8.5 x 10 ⁻⁷	
()-Adrenaline	100	1.0×10^{-6}	
(±)-dl-α-Methylnoradrenaline	100	1.5 x 10 ⁻⁶	
(+)-d-Noradrenaline	25.0 ± 4.9 (4) (0.1 mM)		
(+)-d-Adrenaline	67.0 ± 11.6 (4)	4.5 x 10 ⁻⁶	

Inactive up to 10⁻³ M: Dopamine, (+)-isoprenaline, (±)-octopamine, (±)-normetanephrine, carbuterol, salbutamol

Antagonists	IC _{so} (M)	Antagonists	% Inhibition
(-)-Propranolol	7.0×10^{-7}	(±) Practolol	45.2 ± 2.7 (4) (10 ⁻⁴ M)
(±)-Propranolol	8.3 x 10 ⁻⁷	(±) Dichloroisoprenaline	45.7 ± 7.2 (4) (10 ⁻⁴ M)
(+)-Propranolol	8.4 x 10⁻⁵	(±) MJ 1999	51.5 ± 4.1 (4) (104M)
(-)-Alprenolol	5.0 x 10 ⁻⁶	Phentolamine	44.05 ± 3.3 (7) (10 ⁻⁵ M)
(±)-Alprenolol	5.7 x 10 ⁻⁶		
(+)-Alprenolol	2.0 x 10 ⁻⁵		

Inactive at 10-4M: H35/25: (±)-INPEA

Neuroleptics	% Inhibition at 10 ⁻⁵ M	Neuroleptics	% Inhibition at 10 ⁻⁵ M
Promazine	83.5 ± 4.8 (7)	α-Chlorprothixene	48.9 ± 14.4 (4)
(+)-Butaclamol	73.9 ± 10.4 (3)	β-Clopenthixol	44.9 ± 2.8 (4)
Clozapine	66.2 ± 2.9 (4)	Pimozide	44.6 ± 2.8 (5)
β-Chlorprothixene	57.4 ± 13.3 (4)	Haloperidol	43.5 ± 3.0 (4)
Thioridazine	55.0 ± 5.1 (3)	Trifluperazine	39.6 ± 6.6 (4)
Chlorpromazine	50.9 ± 0.9 (4)	•	
•	$Ki \simeq 1.6 \times 10^{-7} M$	α-Flupenthixol	38.6 ± 2.6 (3)
α-Clopenthixol	48.9 ± 7.0 (4)	β-Flupenthixol	33.9 ± 5.9 (4)
·		(-)-Butaclamol	$23.4 \pm 3.0 (4)$

Inactive at 10-5M: Desmethylimipramine, 7-hydroxy-chlorpromazine, chlorpromazine sulphoxide

EC₅₀: Concentration required for half-maximal stimulation by the agonist. IC₅₀: Concentration of antagonist required to inhibit by 50% the stimulation produced by 50 μ M (–)-NA. Ki: Inhibition constant. In experiments using antagonists or neuroleptics the drug was added 15 min prior to the addition of 50 μ M (–)-NA. Figures in brackets represent the number of determinations. EC₅₀ and IC₅₀ values were estimated graphically from the means of at least four determinations.

maximum stimulation occurred over the range $1 \times 10^{-5} - 5 \times 10^{-5}$ M. A 2.5 fold increase in cyclic AMP levels was routinely obtained. pharmacological characteristics of agonists on this system are summarized in the table. The structures of active and inactive molecules demonstrates the strict requirements for a catechol grouping and a β-hydroxyl group with the correct stereochemistry. The blockade of the stimulation by $5 \times 10^{-5} M$ noradrenaline in the presence of adrenolytics was stereoselective. The selective β_1 antagonist (±)-practolol (Dunlop & Shanks, 1968) was less active than (\pm)-propranolol, whilst the γ (1-(4'-methylphenyl)-2-isoblocker H35/25 propylamino-propranol HCl) (Levy & Wilkenfeld, 1969) was inactive; this is of interest as the β_2 agonist salbutamol (Farmer et al., 1970) was also found to be inactive. The spectrum of activity for the neuroleptics was very different from that found for the blockade of the dopamine sensitive adenylate cyclase (Miller, Horn & Iversen, 1974). Promazine, clozapine, thioridazine and chlorpromazine were all quite active, whereas α-flupenthixol and trifluperazine, both potent blockers of the dopamine sensitive adenylate cyclase, were less active. Assuming the blockade by chlorpromazine is competitive it has an approximate Ki of 1.6 x 10⁻⁷M whereas the value for the inhibition of the dopamine-adenylate cyclase is 4.8×10^{-8} M (Miller et al., 1974). It is also of interest that no large differences in potency were found for the thioxanthene isomers; this contrasts strongly with results obtained from the dopaminergic cyclase (Miller et al., 1974).

References

- BLUMBERG, J.B. & SULSER, F. (1974). The effect of antipsychotic drugs on the 3', 5'-adenosine monophosphate (cAMP) system on rat limbic forebrain. Fed. Proc., 33, 286.
- BLUMBERG, J.B., TAYLOR, R.E. & SULSER, F. (1975). Blockade by pimozide of a noradrenaline sensitive adenylate cyclose in the limbic forebrain: possible role of limbic noradrenergic mechanisms in the mode of action of antipsychotics. *J. Pharm. Pharmac.*, 27, 125-128.
- BROWN, B.L., EKINS, K.D. & ALBANO, J.D.M. (1972). Saturation assay for cyclic AMP using endogenous binding protein. Adv. Cyclic Nucleotide Res., 2, 25-40.
- CHASIN, M., MAMRAK, F. & SAMANIEGO, S.G. (1974). Preparation and properties of a cell-free hormonally responsive adenylate cyclase from guinea pig brain. J. Neurochem., 22, 1031-1038.
- DUNLOP, D. & SHANKS, R.G. (1968). Selective blockade of adrenoceptive beta receptors in the heart. Br. J. Pharmac. Chemother., 32, 201-218.
- FARMER, J.B., KENNEDY, I., LEVY, G.P. & MARSHALL, R.J. (1970). A comparison of the β-adrenoreceptor stimulant properties of isoprenaline, with those of orciprenaline, salbutamol, soterenol and trimetoquinol on isolated atria and trachea of the guinea-pig. J. Pharm. Pharmac., 22, 61-63.
- LEVY, B. & WILKENFELD, B.E. (1969). An analysis of selective beta receptor blockade. Eur. J. Pharmac. 5, 227-234.
- MILLER, R.J., HORN, A.S. & IVERSEN, L.L. (1974). The action of neuroleptic drugs on dopamine-stimulated adenosine cyclic 3', 5'-monophosphate production in rat neostriatum and limbic forebrain. *Mol. Pharmac.*, 10, 759-766.

Altered sensitivity of β-adrenoceptor-mediated cyclic AMP formation in brain

S.R. NAHORSKI* & K.J. ROGERS

Section of Pharmacology, Academic Division of Medicine, University of Sheffield

In several studies using homogenates or slices of brain tissue it has been demonstrated that the stimulation of catecholaminergic receptors causes an increased synthesis of cyclic AMP (Daly, 1975). In our studies of the effects of neurohormones on cerebral cyclic AMP metabolism we have found that the neonate chick with its immature blood-brain barrier is a useful experimental model for both *in vivo* and *in vitro* investigations (Edwards, Nahorski & Rogers, 1974), and we have

provided evidence that catecholamines stimulate formation of the nucleotide in chick cerebral hemispheres via β -adrenoceptors (Nahorski, Rogers & Smith, 1974). In order to assess the potential importance of these responses we have, in the present study, used procedures that alter central adrenergic transmission, in an attempt to determine whether or not there are accompanying changes in the sensitivity of the cyclic AMP response.

Experiments were performed on 1-6 day old male Ranger chicks. Pretreatment with reserpine (2.5 mg/kg s.c.) daily for three days or 6-hydroxydopamine (60 μ g in 10 μ l intracerebroventricularly) on two successive days severely depleted brain catecholamines (> 70%) for at least six days. Five days after commencing the pretreatments, groups of chicks were injected intravenously with (-)-isoprenaline (5 μ mol/kg) or histamine